Mankind Pharma Q2 FY27 Financial Results and Corporate Restructuring Summary
Mankind Pharma Ltd · Others (Uncategorized) · 26 Oct 2026, 8:47 pm
Mankind Pharma Q2 FY27 Financial Results and Corporate Restructuring Summary Mankind Pharma reported consolidated revenue from operations of ₹4,337.86 Cr for the quarter ended 30th Sep'26, up 17.33% YoY from ₹3,697.16 Cr. Consolidated net profit rose 37.67% YoY to ₹716.12 Cr compared to ₹520.18 Cr. For H1 FY27, consolidated revenue reached ₹8,368.45 Cr with net profit at ₹1,290.21 Cr. The Board approved the merger of wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into Mankind Pharma with an appointed date of 1st Apr'27, involving no share issuance or cash outflow.
Original exchange filing (PDF)
More announcements from Mankind Pharma Ltd
- Please find attached intimation regarding change in Corporate Office Address of RTA · 13 Nov 2026
- Please find attached Intimation of participation in the Investor Conference · 06 Nov 2026
- Please find attached intimation regarding ESG Rating · 05 Nov 2026
- Intimation of participation in the Investor Conference. · 03 Nov 2026
- Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27 · 30 Oct 2026
- Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL · 30 Oct 2026
- In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet · 27 Oct 2026
- Please find attached link for audio recording of the Investor Conference Call held on October 26, 2026 · 27 Oct 2026
